Purpose of the Program
- Early detection of immunotoxicity caused by checkpoint inhibitors.
- Management of immune-mediated inflammation in the colon, lungs, and liver.
- Ensuring the continuity of the cancer treatment plan with minimal interruptions.
Receive specialized care for managing immunotherapy side effects effectively, ensuring your treatment journey continues safely while minimizing complications to vital organs like the colon, lungs, and endocrine glands.
Scientific name: Immunotherapy-Related Adverse Events (irAE) Management Program
A comprehensive medical service following precise protocols to monitor and treat immunotoxicity from checkpoint inhibitors, including liver, lung, and endocrine function assessments to ensure patient safety during therapy.